Glycan heterogeneity of the respiratory syncytial virus (RSV) fusion (F) protein was demonstrated by proteomics. The effect of maturation of the virus glycoproteins-associated glycans on virus infectivity was therefore examined using the α-mannosidase inhibitors deoxymannojirimycin (DMJ) and swainsonine (SW). In the presence of SW the N-linked glycans on the F protein appeared in a partially mature form, whereas in the presence of DMJ no maturation of the glycans was observed. Neither inhibitor had a significant effect on G protein processing or on the formation of progeny virus. Although the level of infectious virus and syncytia formation was not significantly affected by SW-treatment, DMJ-treatment correlated with a one hundred-fold reduction in virus infectivity. Our data suggest that glycan maturation of the RSV glycoproteins, in particular those on the F protein, is an important step in virus maturation and is required for virus infectivity.
Introduction
Human respiratory syncytial virus (hRSV) encodes three integral membrane proteins, namely the fusion (F), attachment (G) and small hydrophobic (SH) proteins. The G protein mediates attachment of the virus to the cell during virus entry, while the role played by the SH protein during virus replication remains to be established. During virus entry, the F protein plays a pivotal role by mediating fusion of the virus and host-cell membranes. Studies employing reverse genetics have shown that whereas the F protein is essential for replication in tissue culture, the G and SH proteins are dispensable (Bukreyev et al., 1997; Karron et al., 1997; Whitehead et al., 1999; Techaarpornkul et al., 2001) . The G protein is extensively modified by O-linked glycosylation, but it is not clear to what extent it is modified by N-linked glycosylation. In addition, only minor amounts of the SH protein are N-linked glycosylated. In contrast, of the three virus glycoproteins, the F protein has relatively high levels of N-linked glycans, and evidence suggests a role for N-linked glycosylation of the F protein in mediating virus-mediated cell fusion (Zimmer et al., 2001b) .
The F protein is synthesised initially as an inactive precursor (F0), which undergoes proteolytic cleavage by cellular factors in the trans-Golgi compartment, (Bolt et al., 2001; Gonzalez-Reyes et al., 2001; Sugrue et al., 2001; Zimmer et al., 2001a) . This generates the mature and active form of the protein which consists of the disulphide-linked subunits, F1 and F2 (Scheid and Choppin, 1977; Gruber and Levine, 1985; Collins and Mottet, 1991; Anderson et al., 1992a Anderson et al., , 1992b . During its transport through the secretory pathway, the F protein is glycosylated by several enzyme activities in the endoplasmic reticulum (ER) and Golgi complex (Lambert, 1988) . Depending on the RSV isolate, the F protein amino acid sequence can contain up to 5 potential N-linked glycosylation sites. However, experimental evidence suggests that in the mature F protein, the F1 subunit is glycosylated at a single site, N500, while the F2 subunit is glycosylated at two different sites, namely N27 and N70 (Collins et al., 1984; Baybutt and Pringle, 1987; Lopez et al., 1988; Lerch et al., 1991; Zimmer et al., 2001b) . Recent reports suggest that N500 plays a role in F protein-mediated fusion (Zimmer et al., 2001b) possibly by interacting with the heptad repeat regions. In contrast, the role played by N27 and N70 in the functionality of the F protein remains to be established.
Following the exit of the F protein from the ER, each attached glycan chain exists in a form that is characterised by a mannose core to which chains of mannose residues are attached. These mannose chains are removed subsequently in the Golgi complex by Golgi-resident α-mannosidases 1 and 2 and replaced with other terminal glycans, such as N-acetylglucosamine and fucose. This process changes the structure of the attached glycans from relatively simple structures to glycan chains that exhibit a high degree of complexity (Anderson et al., 1992a (Anderson et al., , 1992b Collins and Mottet, 1991) . N-linked glycosylation of the hRSV F protein does not appear to be required either for its proteolytic cleavage or its surface expression (Collins and Mottet, 1991) . However, although there is no apparent requirement for glycosylation in F protein transport, evidence suggests that it may be required for post-assembly processes that involve the virus glycoproteins (e.g., membrane fusion, Zimmer et al., 2001b) . The work described in this manuscript examines the effect of glycan maturation on virus infectivity. Our results suggest that maturation of the glycans on the virus glycoproteins is not required either for virus assembly or for the incorporation of these proteins into virus particles. However, glycan maturation is required for infectivity of progeny virus. The correlation between glycan maturation and at least one indicator of F protein functionality in tissue culture (i.e., virus infectivity) points to the F protein as the major site of action of DMJ. This suggests that the structure of the glycans that are attached to the F protein may be essential for determining the biological activity of this protein.
Results and discussion
The F protein exhibits heterogeneity in glycan maturation
The effect of glycosylation on F protein heterogeneity was examined by comparing the migration of the glycosylated and de-glycosylated forms of the F protein subunits by 2D SDS PAGE and Western blotting analysis. The F1 and F2 subunits were detected with MAb169 and PAb922, respectively.
RSV-infected cells were solubilised with denaturation buffer and incubated in the presence or absence of PNGase F as described in Materials and methods. This enzyme is able to remove N-linked glycans from proteins. The proteins in these lysates were separated by SDS PAGE, transferred by Western blotting on to PVDF membranes, and the membranes probed either with MAb169 or PAb922 (Fig. 1 ). Following treatment with PNGase F, the F1 subunit changed from a single protein species with a mass of 55 kDa to one of 50 kDa (Fig. 1A) while the F2 subunit changed from a single protein species with a mass of 20 kDa to one of 10 kDa (Fig. 1B ). This showed that both subunits of the F protein were de-glycosylated efficiently by PNGase F treatment and that the glycosylated and nonglycosylated forms of the protein could be detected with these antibodies.
Glycosylation of the F protein subunits from infected cells was examined by 2D SDS PAGE using the above antibodies. Total membranes were recovered from mock-and RSV-infected Hep2 cells at 20 h post-infection (PI) and incubated in the presence or absence of PNGase F, prior to preparation for 2D SDS PAGE as described in Materials and methods. The proteins were separated in the first dimension by isoelectric focusing using a pH range of 3-10 and then separated in the second dimension by SDS PAGE. A major obstacle to the analysis of membrane proteins by 2D SDS PAGE is their hydrophobic nature, which often results in poor resolution. However, the sample preparation procedures described in Materials and methods resulted in good separation and resolution of the membrane-associated proteins by 2D SDS PAGE. This can be seen in silver-stained polyacrylamide gels of membrane proteins from virus-infected cells ( Fig. 2A ).
Following separation in the second dimension by SDS PAGE, the proteins were transferred by Western blotting on to PVDF membranes which were then probed either with MAb169 ( Fig. 2B) or PAb922 (Fig. 2C ) and the positions of the relevant F protein spots were visualised. In the absence of PNGase F treatment, three protein spots were observed when probed with MAb169 ( Fig. 2B (b) ). Two of these were in high abundance while a third protein spot appeared in much lesser abundance ( Fig. 2B (b) , highlighted by *). Each of these proteins migrated with a molecular mass of 55 kDa, the expected size for the F1 protein subunit. Following PNGase F-treatment, one major protein spot with a mass of approximately 50 kDa was observed, which is the expected size for the de-glycosylated F1 subunit, and which accounted for 95% of the total protein detected ( Fig. 2B (c) ). A minor protein of similar size was also detected ( Fig. 2B (c) , highlighted by *), the significance of which is currently unclear. In a similar analysis, in the absence of PNGase F-treatment, probing the membrane with PAb922 showed three major protein species of 20 kDa ( Fig. 2C (b) ). Treatment with PNGase F gave rise to a single major protein species with a mass of 10 kDa ( Fig. 2C (c) ), the expected size for the deglycosylated F2 subunit. A minor protein was also observed ( Fig. 2C (c) , highlighted by *), the significance of which is unclear. In addition, deglycosylation of the F1 and F2 subunits resulted in a shift to a more basic isoelectric point (PI).
The different forms of the F protein subunits, detected by 2D SDS PAGE ( Fig. 2B (b) ; Fig. 2C (b) ), migrated with the same molecular mass, suggesting that the same number of glycosylation sites are used by these different F protein species. Previous studies on recombinant F protein expression have shown that the selective removal of individual glycosylation sites results in significant differences in molecular mass of the subunits (Zimmer et al., 2001b) . When examined by SDS PAGE, the F2 subunit glycosylated at a single site migrates with an apparent size of 3-4 kDa less than the subunit modified at two sites. A similar size difference would be expected in the second dimension if these F2 species differed in the number of attached glycans. The change in isoelectric point presumably is a consequence of the variation in the type of terminal carbohydrates that are attached to the glycans. Although this difference would change marginally the apparent size of the glycoprotein subunit, such subtle alterations would not be expected to give rise to a detectable difference in molecular mass in the second dimension under our electrophoretic conditions.
No protein products smaller than those expected were detected by 2D SDS PAGE, suggesting that there was no proteolytic degradation of the F protein subunits during sample preparation. Similarly, no protein spots were observed in material processed from mock-infected cells ( Fig. 2B (a) ; Fig.  2C (a) ), thus demonstrating the specificity of the antibodies.
Several reports have shown that during RSV infection the G and SH proteins are expressed as glycosylated variants. The RSV G protein is extensively modified by O-linked glycosylation which gives rise to G protein species ranging in size from 45 kDa up to 90 kDa when examined by SDS PAGE. (Lambert, 1988; Wertz et al., 1989; Collins and Mottet, 1992) . Although the vast majority of the SH protein is expressed in a non-glycosylated form, a small proportion of the SH protein is also expressed as an immature N-linked glycosylated form that exhibits endoglycosidase-H sensitivity. A small proportion of the latter is further modified by the addition of polylactosamine (Anderson et al., 1992a (Anderson et al., , 1992b . The function of the different glycosylated forms of these proteins is currently unclear. The proteomic analysis described above suggests that the F protein is expressed in at least two different glycosylated forms, providing evidence that it also exhibits heterogeneity with respect to glycosylation. However, it is not clear if the polypeptide chains within an individual F protein trimer are glycosylated differentially or if glycosylation of the individual F protein trimers is variable.
Maturation of F protein glycans is not required for efficient RSV assembly
The above data provided evidence that during RSV infection, the F protein exhibits heterogeneity with respect to the structure of its attached N-linked glycans. We therefore used the αmannosidase inhibitors, deoxymannojirimycin (DMJ) and swainsonine (SW), which inhibit N-linked glycan maturation (reviewed in Elbein, 1991) , to investigate the effect of such maturation on the functionality of the F protein. The attached Nlinked glycans are synthesised initially as structures consisting of mannose chains, which are then partially removed by the cellular enzymes α-mannosidase 1 and α-mannosidase 2. This leaves a mannose core ( Fig. 3A) to which other glycan moieties, such as N-acetyl-glucosamine and fucose, are added by specific glycotransferases. This process converts the attached glycans from simple structures, that consist almost entirely of mannose, into structures that exhibit a high degree of complexity. DMJ and SW inhibit the activity of α-mannosidase 1 and αmannosidase 2, respectively, which prevents maturation of the attached glycans, and to varying degrees, the incorporation of terminal sugar moieties (e.g., N-acetyl-glucosamine) into the glycan chains.
Virus-infected Hep2 and Vero cells were pulse-labelled with [ 35 S]methionine or [ 3 H]glucosamine for 3 h in the absence (NT)
or presence of either DMJ or SW (Figs. 3B-D) after which the cells were incubated for an extra 1 h in DMEM (containing nonradioactive methionine) in the absence or presence of the inhibitors. The F protein was isolated by radioimmunoprecipitation (RIP) using MAb19 and examined using SDS PAGE (Figs. 3B and C). Analysis of the [ 35 S]methionine-labelled proteins revealed the cleaved, mature F protein as the major form detected (Fig. 3B ). In the absence of inhibitor, the F1 subunit was detected as a single protein species with a mass of approximately 55 kDa and the F2 subunit migrated with a mass of approximately 20 kDa. A small degree of size variation in the protein products from the two cell lines was observed, which reflects presumably certain cell-specific differences in F protein processing. Similar cell-specific changes have been reported for the G protein (Garcia-Beato et al., 1996) . The presence of DMJ or SW did not affect the conversion of F0 into the mature F protein by cellular protease activity and the levels of [ 35 S] methionine-labelled F protein were similar in both non-treated and inhibitor-treated cells. However, a slight reduction in the apparent molecular mass of the F2 subunit was observed in both cell lines in the presence of the glycosylation inhibitors, which is presumably due to changes in the structure of the attached glycans. In particular, the relatively high levels of mannose, which would be expected to be present in the F protein following treatment with these α-mannosidase inhibitors, may affect their apparent size when examined by SDS PAGE.
In a parallel analysis, the F protein was isolated from mocktreated and DMJ-or SW-treated infected Hep2 and Vero cells that were [ 3 H]glucosamine-labelled and examined by SDS PAGE (Fig. 3C) . In both the absence and presence of SW, protein species of similar intensities, which corresponded in size to the F1 and F2 subunits, were visible ( Fig. 3C ). However, in the presence of DMJ, a large reduction occurred in the levels of [ 3 H]glucosamine incorporated into the F1 and F2 subunits. This is in contrast to the presence, in all samples, of similar levels of [ 35 S]methionine-labelled F protein being detected by SDS PAGE (Fig. 3B ). Thus, while there appears to be an incorporation of glucosamine into the F protein subunits in the presence of SW, only a minimal addition of terminal glycans, such as glucosamine, is apparent in the presence of DMJ.
In addition to isolation of the F protein, the G protein was isolated from the [ 3 H]glucosamine-labelled mock-treated and DMJ-treated infected Hep2 and Vero cells by RIP using MAb30, whose specificity has been described previously (Jeffree et al., 2003) . Examination of the G protein by SDS PAGE (Fig. 3D ) showed protein products of the expected sizes which were similar both in the presence or absence of DMJ. As observed previously, the G protein expressed in Hep2 cells differed in band pattern from that in Vero cells (Garcia-Beato et al., 1996) . However, compared to mock-treated cells, only a small reduction in [ 3 H]glucosamine labelling of Hep2 cells was observed in the presence of DMJ and no obvious reduction occurred in similarly treated Vero cells. Similarly, the size of the G protein species was similar in both mock-and DMJ-treated cells. This is consistent with the G protein being extensively modified by O-linked glycosylation, a process that is not affected by DMJ. This finding is consistent with previous findings that tunicamycin, an inhibitor of N-linked glycosylation, did not interfere with the modification of the G protein by O-linked glycosylation (Wertz et al., 1989) . The results obtained for F and G protein labelling in the presence and absence of DMJ were similar in both cell lines, suggesting that the effect of this inhibitor on processing of the RSV glycoproteins is not cellspecific. Although the G protein in the RSV A2 sequence contains four potential N-linked glycosylation sites, it is not clear either how many of these are utilised or what role N-linked glycosylation plays in the functionality of the G protein.
In a further analysis, the endoglycosidase-H (endo-H)sensitivity of the F protein in non-treated and inhibitor-treated cells was examined. Endo-H is able to remove simple glycans from proteins while mature glycan chains containing complex sugars remain unaffected. RSV-infected Hep2 cells were pulselabelled with [ 35 S]methionine for 3 h in the absence or presence of the glycosylation inhibitors. The F protein was isolated by RIP, incubated at 37°C for 14 h in the presence or absence of endo-H as described in Materials and methods and examined by SDS PAGE (Fig. 4A ). The F protein is expressed initially as the endo-H sensitive precursor, F0 (75 kDa), which is subsequently modified by the addition of complex carbohydrates in the Golgi apparatus to produce the endo-H-resistant form of the protein (Collins and Mottet, 1991; Anderson et al., 1992a Anderson et al., , 1992b .
Maturation of the N-linked glycans coincides with the posttranslational cleavage of F0 into the F1 (55 kDa) and F2 (20 kDa) subunits. In both non-treated and inhibitor-treated cells, the F0 is converted into a de-glycosylated, 60 kDa protein Fig. 5 . Distribution of the F protein in virus-infected cells following treatment with DMJ or SW. RSV-infected cells were either non-treated (NT) or treated with DMJ or SW, labelled with MAb19 and visualised by fluorescence microscopy as described in Materials and methods. The presence of small virus filaments (VF) is highlighted. Fig. 6 . Distribution of the F and G proteins within the envelope of RSV filaments. RSV-infected cells were either non-treated (NT), SW-or DMJ-treated and processed for FE SEM as described in Materials and methods. The cells were labelled either with MAb19 (F protein, plates A-D) or MAb30 (G protein, plates E and F) and the presence of bound antibody detected using secondary antibody conjugated to 10 nm colloidal gold particles. The bound gold was visualised as white spots in the BSE images. The individual images obtained using the secondary electron (SE) and backscatter electron (BSE) detectors are shown. The virus filaments (VF) and 10 nm colloidal gold particles (white arrows) are highlighted. species following endo-H treatment, thus acting as a positive control in this analysis. In non-treated cells, the apparent mass of the F protein subunits is unaffected by endo-H treatment, showing, as expected, that it is converted into the endo-H resistant form of the protein. In contrast, in the presence of either DMJ or SW, the F protein was expressed in an endo-H sensitive form, since treatment with the enzyme produces a shift from 55 kDa to 50 kDa and a shift from 20 kDa to 10 kDa, the expected sizes of the non-glycosylated F1 and F2 protein subunits, respectively. This suggests that although different levels of terminal glycans are incorporated into the F protein following DMJ-and SW-treatment, in each case they have not been fully processed into mature glycans.
The above data suggested that DMJ treatment prevented heterogeneity of the F protein glycans. Evidence of the loss of this heterogeneity following DMJ treatment was supported by 2D SDS PAGE (Fig. 4B) . The migration pattern of the F1 subunit isolated from non-treated or DMJ-treated cells was compared. In non-treated cells, several F1 subunit species were detected which differed in their isoelectric points ( Fig. 4B (a) ) and were similar to those described above ( Fig. 2A (b) ). In contrast, protein isolated from DMJ-treated cells migrated as a single species (Fig. 4B (b) ), which had undergone a shift to a more basic isoelectric point, presumably as a result of the absence of complex glycans following DMJ treatment.
Previous studies have shown that certain post-translational modifications, such as cleavage of the F protein by proprotein convertases, are required for RSV assembly (Bolt et al., 2000; Sugrue et al., 2001) . Thus the effect of these glycosylation inhibitors on both virus assembly and on the incorporation of the virus glycoproteins into virus filaments (VF) was examined. Non-treated and inhibitor-treated virus-infected cells were labelled with MAb19 and the distribution of the F protein was examined by fluorescence microscopy. In all cases, the presence of small VF was observed and the cells showed similar levels of labelling, suggesting that neither DMJ nor SW appeared to inhibit virus assembly or prevent targeting of the F protein into progeny virus (Fig. 5 ). This is consistent with previous findings by FACS analysis which had suggested that neither DMJ nor SW reduced surface expression of the F protein in virus-infected cells (MacLellan and Sugrue, data not shown).
The fluorescence microscopy results were confirmed by field emission scanning electron microscopy (FE SEM) whose use in the analysis of RSV-infected cells has been described previously (Jeffree et al., 2003) . This allows both visualisation of the maturing RSV filaments in greater detail and the semiquantitative determination of glycoprotein levels (e.g., the F protein) within the VF. FE SEM has an advantage over FACS analysis since it makes possible the detection of signal present on the VF, whereas FACS detects all surface signal (i.e., fluorescence) and does not distinguish between VF-associated and non-VF-associated signal. Non-treated and inhibitor-treated infected cells were labelled with MAb19 and the presence of bound antibody was detected using secondary antibody conjugated to 10 nm colloidal gold. The VF were visible using the secondary electron (SE) detector (Fig. 6, plate A) , while the back scatter electron (BSE) detector allowed the visualisation of bound MAb19 indicating the presence of the F protein ( Fig. 6, plates B-D) . In the BSE images, the outline of the VF can be seen due to the use of osmium tetroxide in the specimen preparation which stains the VF and causes some residual back scatter signal. However, in BSE mode, the presence of colloidal gold is visible as small white spots on the VF. These data show that similar levels of bound antibody were present within the VF of both non-treated and treated cells, suggesting that glycan maturation did not influence the targeting of the F protein to the sites of virus assembly. Furthermore, we noted the presence of similar levels of virus filaments in the presence and absence of the α-mannosidase inhibitors, suggesting that these inhibitors did not impair budding efficiency.
The labelling pattern of the G protein in the absence or presence of DMJ was also examined by FE SEM. In this analysis, the G protein was detected with MAb30. In the absence of inhibitor, a pattern of labelling was observed which was similar to that observed previously (Jeffree et al., 2003) . In addition, similar levels of G protein labelling were observed both in the absence or presence of DMJ, suggesting that targeting of this protein into VF was unaffected by DMJ treatment (Fig. 6 , plates E and F). Although the pattern of antibody labelling for the F and G proteins was similar in both mock-treated and DMJ-treated cells, labelling of VF with MAb30 was approximately three times more than that observed with MAb19. The reason for this apparent difference in goldlabelling is at present unclear but may be due to some masking of the F protein epitope during fixation with glutaraldehyde. Labelling of the VF with MAb19 was more sensitive to the concentration of glutaraldehyde present in the initial fixation solution than was found when labelling with MAb30. However, these data show similar levels of the F and G proteins within the virus envelope of mock-treated and DMJ-treated cells. Fig. 7 . Analysis of F protein levels in cell-released virus. Cell-released virus was prepared from non-treated (NT), SW-or DMJ-treated [ 35 S]methionine-labelled cells as described in Materials and methods. The virus particles were detergentsolubilised with lysis buffer and the F, N and P proteins isolated by RIP using anti-RSV and examined either by (A) 7.5% or (B) 15% SDS PAGE.
The above results were confirmed by examining the protein content of cell-released virus to determine if the glycosylation inhibitors caused a reduction in the levels of F protein incorporated into cell-free virus. Hep2 cells were infected with RSV in the absence or presence of the glycosylation inhibitors and labelled with [ 35 S]methionine. The total amount of cell-free virus from these cells was harvested at 60 h PI as described in Materials and methods. The virus particles were solubilised with detergent to extract the virus-associated proteins which were isolated by RIP using anti-RSV, a composite antibody preparation which recognises the N, P and F proteins (Wright et al., 1997) . This analysis showed similar amounts of the major structural proteins, including the F1 and F2 subunits, in virus harvested from both non-treated and inhibitor-treated cells (Figs. 7A and B) , indicating that these inhibitors did not impair either the levels of released virus or the incorporation of these structural proteins into the released virus. Thus, the FE SEM and RIP data provide evidence that efficient incorporation of the F protein into virus particles is not dependent upon glycan maturation. This suggests that these inhibitors cause neither gross mis-folding of the F protein nor inhibition of its oligomerisation, otherwise interference both with the transport of the F protein through the secretory pathway and its subsequent incorporation into newly formed virus particles would be expected.
Glycan maturation is required for virus-infectivity
Maturation of the F protein-associated N-linked glycans did not appear to prevent virus assembly and therefore the effect of glycan maturation on virus infectivity was examined. Hep2 cells were infected with RSV in the presence or absence either of SW or DMJ and the virus produced both in the absence and presence of these inhibitors was analysed further to determine if they had any deleterious effect on virus infectivity. In the absence of inhibitor, as expected, the appearance of extensive syncytia was observed by 48 h PI (Fig. 8A , highlighted by black arrow). A similar effect was observed with infected cells incubated in the presence of SW. In contrast, cells treated with DMJ exhibited a low level of syncytia formation and the cell monolayer remained largely intact throughout the infection. This suggested that in the presence of DMJ, the ability of the F Fig. 8 . The effect of α-mannosidase inhibitors on RSV infectivity. (A) Hep2 cells were either mock-infected or infected with RSV at a moi of 0.1. At 6 h PI, duplicate cultures were left either untreated (NT) or treated with SW or DMJ. At 48 h PI, the cells were photographed using a Pentax K1000 camera attached to a low-power inverted microscope (Zeiss Axiovert 25). Virus-induced syncytia are highlighted (black arrows). (B). The infectivity of virus, recovered from non-treated, SW-or DMJ-treated cells harvested at 60 h PI, was measured using a microplaque assay as described in Materials and methods. protein to mediate membrane fusion was impaired, and that maturation of F protein-associated glycans is important for this biological activity.
The virus was harvested from the inhibitor-treated and nontreated cells at 60 h PI and the infectivity of the recovered virus was measured (in the absence of added inhibitor) using a microplaque assay as described previously (Cannon, 1987; Sugrue et al., 2001) . The infectivity of virus harvested from SW-treated cells showed an approximate two-fold reduction compared to that from non-treated cells whereas the effect of DMJ treatment was much more dramatic with infectivity levels reduced one hundred-fold (Fig. 8B) .
The difference between the two α-mannosidase inhibitors with regard to F protein processing and their respective antiviral activities is unclear. DMJ inhibits α-mannosidase 1 while SW inhibits α-mannosidase 2. Thus, it appears that SW inhibits glycan maturation at a later stage in the maturation process. This suggests that in the presence of SW, a degree of glycan maturation occurs, leading to the formation of hybrid glycans and this has been observed previously (Elbein, 1984; Moremen, 2002) . In contrast, no maturation of the attached glycans occurs in the presence of DMJ. It is possible, therefore, that the virus glycoproteins may be able to accommodate some loss of glycan maturation without a serious loss of biological activity.
The data presented here provide evidence that maturation of the glycans present on the virus glycoproteins is required for virus infectivity. Furthermore, DMJ-treatment appears to have a much more dramatic effect on the glycosylation status of the F protein than on that of the G protein. Under conditions where the maturation of N-linked glycans is prevented (i.e., DMJ-treatment), a 100-fold decrease in virus infectivity was observed. Furthermore, DMJ treatment correlated with a vast reduction in syncytia formation in virus-infected cells. These two observations suggested that DMJ caused an impairment of the F protein function. A reduction in syncytia formation via some unidentified host cell factor that is involved in mediating virus fusion cannot be unequivocally ruled out. However, recent studies on another paramyxovirus, measles virus (MV), showed that DMJ treatment neither prevented syncytia formation in MV-infected Hep2 cells nor did it result in a significant reduction is virus infectivity (Bolt et al., 1999) . Therefore, in contrast to the situation in RSV, the addition of complex glycans to the MV glycoproteins appears not to be required for mediating membrane fusion. Additionally, this suggests that DMJ does not modify general host-cell factors that may be required for virus-mediated cell fusion. In contrast, we noted that SW-treatment produced no apparent reduction in the syncytia levels, nor a significant effect on virus infectivity. Since syncytia formation is an indicator of fusion activity, it is possible that the ability of the virus to mediate cell fusion is impaired which leads to a reduction in virus infectivity.
RSV generated by reverse genetics, in which the G or SH proteins are deleted, is able to replicate in tissue culture and such studies have shown that only the F protein is required for virus-mediated cell fusion (Karron et al., 1997; Whitehead et al., 1999; Techaarpornkul et al., 2001) . Although a reverse genetics approach has suggested that the G protein may facilitate virus binding, it has no significant involvement in the virus-mediated cell fusion process (Techaarpornkul et al., 2001) . This suggests that the reduction in virus infectivity in the presence of DMJ may be a consequence of aberrant processing of the F protein. In several different paramyxoviruses, the ability of the respective fusion proteins to induce fusion has been shown to be dependent upon the presence of specific N-linked glycans (Malvoisin and Wild, 1994; Bolt et al., 1999; McGinnes et al., 2001; von Messling and Cattaneo, 2003; Wang et al., 2004) . In RSV, it has been suggested that glycosylation of the F protein, and in particular the single glycan moiety on the F1 subunit, is required for membrane fusion (Zimmer et al., 2001b) . These studies revealed that the removal of glycan N500 from the F1 subunit resulted in a dramatic reduction in F protein fusion activity, whereas removal of the individual glycans from the F2 subunit appeared to have no strong deleterious effect. These findings have been confirmed in our laboratory by examining the ability of the RSV F protein (A2 sequence) to mediate membrane fusion following the selective removal of specific glycosylation acceptor sites (Li, 2005) . Thus, a role for glycan N500 in the F protein-mediated cell fusion mechanism is suggested and it is interesting to note that this glycan attachment site is located within the heptad repeat region of the F1 subunit (Chambers et al., 1990) . Within viral fusion proteins, heptad repeat sequences form structures that play an important role during virus-induced cell fusion (reviewed in Lamb, 1993; Dutch et al., 2000; Colman and Lawrence, 2003; Morrison, 2003; Yin et al., 2005) and it is possible that N500 may interact with these RSV F protein structures. The results presented here suggest that F protein-induced cell fusion, and hence virus infectivity, may also be dependent both upon the structure of the attached glycan. Thus, an indirect effect of glycan maturation on the fusion process is implicated, possibly by facilitating the adoption of the fusionactive form of the RSV F protein.
An alternative to the above explanation for our observations is the possibility that glycan maturation is required for cell attachment. Glycan maturation may be required for receptor binding to susceptible cells and it is possible that DMJ may block the attachment of newly assembled virus particles to the cells thus preventing indirectly the formation of syncytia. It is unlikely that DMJ would influence virus attachment by affecting the RSV cell receptor heparin sulphate (HS), since glycoaminoglycans (GAGs), such as HS, are synthesised by cellular pathways that do not involve α-mannosidase 1, and furthermore, GAGs are attached to serine residues within proteins via O-linked glycosylation (reviewed in Hacker et al., 2005) . However, the role played by the F protein in virus binding to cell surface GAGs has been demonstrated previously (Karger et al., 2001 ) and more recent evidence suggests an involvement of the F2 subunit during the initial stages of cell attachment (Schlender et al., 2003) . It is possible that the structure of the glycans present within the F2 subunit may be important for this interaction.
RSV infection can cause severe bronchiolitis in infants and in certain high-risk groups within the adult population such as the elderly and immunocompromised and there is currently no effective vaccine to protect such individuals from infection. The only currently effective preventative measure is the use of humanised monoclonal antibodies, which are both expensive and require specialists for their administration. The reduction in virus infectivity induced by DMJ may have implications for the development of strategies to prevent RSV infection in these high-risk groups. Toxicity data for DMJ in animals are not available and it is not proposed that this specific compound would be used to control RSV infection. However, this class of compound may provide a means of controlling RSV infection by inhibiting the maturation of associated glycans and hence targeting the biological activity of the F protein. It is envisaged that DMJ may serve as a starting point, which, in conjunction with combinatorial chemistry, can be used to generate cost-effective, non-toxic, small molecule antiviral compounds.
Materials and methods

Cells and viruses
The RSV A2 strain was used throughout this study. The Hep2 cell line was maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% foetal calf serum (FCS) and antibiotics.
Antibodies and inhibitors
The F2 protein subunit polyclonal antibody (PAb922) was prepared as follows. A branched peptide corresponding to the sequence TELQLLMOSTQAT, which is present in the F2 domain of the RSV A2 strain, was synthesised on tetravalent (Lys) 2 -Lys-β-Ala-Wang resin (Novochem) using standard 9fluorenylmethoxycarbonyl-solid phase chemistry and an Advanced ChemTech 348 Ω automated peptide synthesiser. The resulting peptide was used to immunise rabbits. The F protein monoclonal antibody (MAb169) was prepared from recombinant F protein expressed in E. coli . MAb19 and MAb30 were gifts from Geraldine Taylor (IAH, Compton, UK) and the anti-RSV monoclonal antibody (NCL-RSV3) was purchased from Novocastra Laboratories. The glycosylation inhibitors, deoxymannojirimycin and swainsonine, were purchased from Calbiochem and stock solutions were prepared in PBSA and used at 2 mM and 0.4 μM, respectively.
Radiolabelling
Cell monolayers were washed with PBSA and incubated in DMEM minus either methionine or glucose containing 100 μCi/ ml [ 35 S]methionine or D-[6-3 H]glucosamine hydrochloride, respectively. When labelling was performed in the presence of inhibitors, the cells were treated with the inhibitors both for 1 h prior to radiolabelling and throughout the period of labelling. In pulse-chase experiments the chase was performed in normal DMEM containing methionine.
Radioimmunoprecipitation (RIP)
This was performed as described previously (Sugrue et al., 2001) . Briefly, cell monolayers were extracted at 4°C in lysis buffer (1% NP-40, 0·1% SDS, 150 mM NaCl, 1 mM EDTA, 2 mM PMSF, 20 mM Tris-HCl, pH 7.5) and the clarified lysate incubated with the primary antibody. The immune complexes were isolated with protein A-Sepharose and the F protein examined by SDS-PAGE. [ 35 S]methionine-labelled protein bands were detected using a Bio-Rad personal Fx phosphorimager and analysed with Quantity one software (Bio-Rad, ver. 4) whereas D-[6-3 H]glucosamine-labelled proteins were detected by fluorography. Apparent molecular masses were estimated using 14 C-methylated proteins (Amersham) in the molecular mass range 14·3-220 kDa.
Endoglycosidase digestion
Protein samples were incubated at 100°C for 10 min in denaturation buffer (0·5% SDS, 1% mercaptoethanol). The samples were then made up to a final concentration of either 50 mM sodium phosphate, 1% NP-40, pH 7·5 or 50 mM sodium citrate, pH 5·5 and incubated at 37°C for 14 h with 1000 u PNGase F (NEB) or 1000 u endo-H (NEB), respectively.
2D SDS PAGE
Membranes were isolated from mock-and virus-infected cells as described previously . Briefly, the isolated membranes were washed twice with 10 mM Tris pH 7.4/1 mM MgCl 2 , resuspended in denaturation buffer and incubated at 100°C for 10 min. The denatured proteins were assayed for protein using the Amersham PlusOne 2-D Quant kit and 50 μg of each sample were incubated overnight at 37°C in the absence or presence of 1000u PNGase F. Proteins were then precipitated in 6% TCA containing 60 mM sodium deoxycholate, resuspended in urea/CHAPS buffer (8 M urea, 2.6 M thiourea, 4% CHAPS, 20 mM Tris pH 7.4, 30 mM DTT, 2% IPG buffer pH 3-10, 2 mM PMSF, EDTA-free complete protease inhibitors) and incubated at room temperature overnight. 40 μg protein in 125 μl were then added to each 7 cm pH 3-10 IPG dry strip and the strips were hydrated overnight at 20°C. The proteins were separated by isoelectric focusing using the IPGPHOR isoelectric focusing system with the following programme.
Step 1: 500 V for 30 min (250 Vh);
Step 2: 1000 V for 30 min (500 Vh); Step 3: 8000 V for 1 h (8000 Vh). After completion of the first dimension, the IPG strips were incubated in SDS equilibration buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS, 0.01% DTT) for 15 min at room temperature. The proteins were then separated in the second dimension by SDS PAGE prior to Western blot analysis.
Western blotting
Western blotting was performed as described previously (Brown et al., 2002) . Briefly, proteins were separated by SDS PAGE after which they were transferred by Western blotting on to PVDF membranes. The membranes were washed, blocked with 1% Marvel, 0.05% Tween in PBSA and probed with specific primary antibodies for 1 h. The membranes were then washed, probed either with goat anti-mouse or anti-rabbit IgG (whole molecule) peroxidase conjugate (Sigma) as appropriate and the protein bands visualised using the ECL protein detection system (Amersham). Apparent molecular masses were estimated using Rainbow protein markers (Amersham) in the molecular weight range 14.3-220 kDa.
Field emission scanning electron microscopy (FE SEM)
This was performed as described previously (Jeffree et al., 2003) . Cells on glass coverslips were infected with RSV and incubated overnight at 33°C in the absence or presence of the glycosylation inhibitors. Cells were fixed with 0.1% glutaraldehyde in PBS at 4°C for 30 min. The fixed monolayers were incubated in PBS supplemented with 2 mM lysine for 20 min and then washed extensively with PBS. The cells were incubated at 25°C for 4 h with MAb19 or MAb30, washed, and then incubated for a further 4 h with goat anti-mouse IgG (whole molecule) conjugated to 10 nm colloidal gold. The monolayers were washed with PBS, fixed with 2.5% glutaraldehyde in PBS and processed for SEM. The samples were visualised in a Hitachi 4700F field emission scanning electron microscope using appropriate settings and digital images were recorded using Hitachi FE PCSEM (ver 3.2) software.
Isolation of [ 35 S]methionine-labelled virus by sucrose gradient centrifugation
Three sub-confluent T75 flasks containing Hep2 cells were infected with RSV at a moi of 1.0 and incubated at 33°C. At 6 h PI, the cells were washed with PBS and 20 ml DMEM minus methionine containing 100 μCi/ml [ 35 S]methionine was added. The flasks were either left untreated (NT) or incubated in the presence of 0.4 μM swainsonine (SW) or 2 mM deoxymannojirimycin (DMJ). The All subsequent steps were performed at 4°C. The tissue culture medium was harvested at 60 h PI and clarified by low speed centrifugation (2000 g, 10 min). Equal volumes (18 ml) of the clarified medium was then centrifuged at 26,000 × g for 90 min and the pelleted material resuspended in 1 ml Hanks buffered saline solution (HBSS) using a sonicating water bath. The resuspended material was overlaid on a 25-55% sucrose gradient (in HBSS) and centrifuged at 26,000 × g for 8 h at 4°C. The virus band was harvested (2 ml) from the gradient (typically at 40% sucrose), resuspended in HBSS and the virus pelleted by centrifugation at 26,000 × g for 90 min. The virus was then resuspended in HBSS and used in RIP assays.
Microplaque titration of RSV preparations
Titrations were performed in 96-well tissue culture plates which were seeded with Hep2 cells (Cannon, 1987) . Tissue culture medium from non-treated and treated mock-and RSVinfected cells was subjected to low-speed centrifugation to remove cell debris (2000 × g/10 min), serially diluted in DMEM + 2% FCS and 50 μl per well of the mock-infected or virus-infected cell supernatant adsorbed for 2 h at 33°C. After adsorption, the inoculum was replaced with DMEM + 2% FCS and incubated at 33°C for 48 h. All further manipulations were performed at 25°C. The monolayers were washed with PBS and fixed with methanol for 20 min. The fixative was removed and the plates were washed with PBS. The monolayers were incubated with an anti-RSV MAb (Novacastra) (50 μl per well diluted 1/100) for 60 min, washed with PBSA and then incubated for a further 60 min with a rabbit anti-mouse IgG MAb conjugated to HRP (50 μl per well diluted 1/100). The plates were washed with PBS, stained with 200 μg/ml 3-amino-9-ethylcarbazole, 0·05% hydrogen peroxide, 20 mM sodium acetate pH 5·5 and the microplaques were counted using a lowpower inverted microscope.
